Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers

BJU International

Volumn 101, Issue 3, 2008, Pages 299-304

  Boorjian, Stephen A ^a   Karnes, R Jeffrey ^a   Rangel, Laureano J ^a   Bergstralh, Eric J ^a   Frank, Igor ^a   Blute, Michael L ^a,b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Gleason score; Prostate cancer; PSA; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 37849013428     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07269.x     Document Type: Article

References (20)

1. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data fromCaPSURE). J Urol 2003 170 : S21 5
2. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998 280 : 969 74
3. Kane CJ, Presti JC, Amling CL, Aronson WJ, Terris MK, Freedland SJ. Changing nature of high risk patients undergoing radical prostatectomy. J Urol 2007 177 : 113 7
4. Perrotti M, Rabbani F, Russo P, Solomon MC, Fair WR. Early prostate cancer detection and potential for surgical cure in men with poorly differentiated tumors. Urology 1998 52 : 106 10
5. Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 2002 168 : 525 9
6. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005 293 : 2095 101
7. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer- specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005 294 : 433 9
8. Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR. Treatment of patients with high risk localized prostate cancer: results form cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 2005 173 : 1557 61
9. Do TM, Parker RG, Smith RB, Kagan AR. High-grade carcinoma of the prostate: a comparison of current local therapies. Urology 2001 57 : 1121 7
10. Rioux-Leclercq NC, Chan DY, Epstein JI. Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 810 adenocarcinoma. Urology 2002 60 : 666 9
11. Mian BM, Troncoso P, Okihara K et al. Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol 2002 167 : 1675 80
12. Manoharan M, Bird VG, Kim SS, Civantos F, Soloway MS. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of ≥8. BJU Int 2003 92 : 539 44
13. Sciarra A, Gentile V, Voria G et al. Role of radical retropubic prostatectomy in patients with locally advanced prostate cancer: the influence of Gleason score 8-10. Urol Int 2003 70 : 186 94
14. Hurwitz MD, Schultz D, Richie JP et al. Radical prostatectomy for high-grade prostate cancer. Urology 2006 68 : 367 70
15. Lau WK, Bergstralh EK, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer. influence of concomitant pathological variables. J Urol 2002 167 : 117 22
16. Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 2003 169 : 157 63
17. Aihara M, Lebovitz RM, Wheeler TM, Kinner BM, Ohori M, Scardino PT. Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. J Urol 1994 151 : 1558 64
18. Hanks GE, Pajak TF, Porter A et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92-02. J Clin Oncol 2003 21 : 3972 8
19. Konety BR, Eastham JA, Reuter VE et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 2004 171 : 709 13
20. Seay TM, Blute ML, Zincke H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol 1998 159 : 357 64